12.03.2021
AKESO GUANGZHOU MANUFACTURING BASE PROJECT PHASE I GOES INTO OPERATION
03.03.2021
CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) OBTAINED ORPHAN DRUG DESIGNATION FROM FDA OF THE UNITED STATES FOR TREATING CERVICAL CANCER
30.07.2020
Akeso, Inc. Promotes the Deployment of Innovative Pipeline Global Cooperation Appoints Dr. Michael (Chen) Chen as Business Development Vice President
Who We Are?
About Us

Akeso,Inc. (HKEX Code: 9926.HK) is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. The Company dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Akeso’s vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.
 
The Company’s business is designed to drive success through both efficient and breakthrough R&D innovation. Since its inception, the Company has had the foresight to develop an end-to-end platform, Akeso Comprehensive Exploration platform (“ACE Platform”), encompassing comprehensive drug discovery and development functionalities, including target validation, antibody drug discovery and development, CMC, and GMP-compliant manufacturing...

Collaborations
Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

图层 0 (4) logo图层 2 (1) logo图层 1 (1) logo图层 3 (1) logo图层 4 (1) logo
Pipelines
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

组 6 (2) logo